Ensysce Biosciences Sets September 2021 Conference Schedule

August 31, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 31, 2021 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, is scheduled to participate at the following industry and financial conferences during September 2021:10th Annual Gateway ConferenceDate and Time: Held virtually...

Read more

Gemina Labs Announces Research and Development Appointments

August 30, 2021 12:40 PM

VANCOUVER, BC / ACCESSWIRE / August 30, 2021 / Gemina Laboratories Ltd. (CSE:GLAB) (the "Company" or "Gemina") is pleased to announce several key hires within our Research and Development team.Research and Development AppointmentsWithin the Research and Development group, the Company has expanded its development competencies with the appointment of Elliot Hong as Vice President of Product Development. Mr. Hong is a mechanical engineer with over...

Read more

EV Biologics Updates on NFT Warrant Dividend Distribution

August 30, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / August 30, 2021 / EV Biologics Corp, (OTC Pink:YECO), today updated shareholders with further details about its NFT Warrant Dividend distribution.The Company is currently finalizing its filing with FINRA, and then will have its transfer agent issue the dividend Warrant through DTC. As previously announced, YECO's shareholders-of-record on July 30, 2021, will receive a Warrant to exercise their right to accept...

Read more

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

August 26, 2021 4:01 PM

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL- Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (EU), addressing an urgent unmet medical need- In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory...

Read more

Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule

August 26, 2021 7:30 AM

Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4)Blinded interim analysis from Phase 2/3 study expected in current quarterTORONTO, ON / ACCESSWIRE / August 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on a Phase 2/3 clinical study evaluating the company's...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

August 25, 2021 10:45 AM

MOUNT VERNON, NY / ACCESSWIRE / August 25, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

BioLargo's Tonya Chandler to Present with Expert Panel at Sustain SoCal's Water Solutions 6 Web Conference on August 26, 2021

August 25, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / August 25, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced its participation in Water Solutions 6, the sixth annual water innovation focused conference run by Sustain SoCal, a leading cleantech industry advocacy organization in Southern California (https://sustainsocal.org). The event takes place on August 26, 2021...

Read more

Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor

August 24, 2021 9:00 AM

BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today the presentation of preclinical data for PRS-220, a connective tissue growth factor (CTGF) inhibitor the Company is developing for the treatment of idiopathic...

Read more

Dr. AnnaRx(TM) Launching CBD & CBN Nutraceutical Line

August 24, 2021 8:45 AM

CAPE TOWN, SA / ACCESSWIRE / August 24, 2021 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update:The Dr AnnaRxTM CBD and CBN range has been finalized. The four initial products to be released are:CBD Energy: Amplify energy and focus to keep you productive throughout the day.CBD...

Read more

ITOCO Welcomes Mr. Erik Gordillo Enamorado as Project Coordinator Carbon Credits and Chief Agricultural Liaison

August 24, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / August 24, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce that Mr. Erik Gordillo Enamorado has joined ITOCO as Project Coordinator Carbon Credits and Chief Agricultural Liaison.Mr. Enamorado is an Agronomist Engineer with a specialty in Agricultural Economics from the Universidad Autónoma Chapingo, Texcoco, Mexico. His studies focused on developing expertise in Agribusiness, Agriculture, and...

Read more

Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th

August 23, 2021 7:00 PM

TUCSON, AZ / ACCESSWIRE / August 23, 2021 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation, is excited to be one of 5 medical companies selected to present at the 2021 Annual Southwest Venture Madness competition. There were over 120 companies who submitted applications for this year's competition. The companies who submitted applications fell...

Read more

Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives

August 23, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the Co-Development plan is to bring new pharmaceutical drug formulations to market with a focused approach that aims to reduce overall costs and time to commercialization.Oncology Pharma is focusing on rare pediatric cancers. Pediatric cancers are traditionally...

Read more

Dr. Southey and Dr. Zarrebini Join M2Bio Sciences and Establish M2Bio Blockchain Research and Technology Group

August 19, 2021 10:30 AM

CAPE TOWN, SA / ACCESSWIRE / August 19, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:WUHAN GENERAL GROUP, in partnership with Catena. MBA, has formed the M2Bio Blockchain Research and Technology Group. The company is committed to its long-term vision and mission to improve...

Read more

Pressure BioSciences, Inc. Reports Strong Second Quarter 2021 Financial Results

August 19, 2021 9:45 AM

Significant Growth Reported in Total Revenue (127%), Instrument Sales (178%), and BaroFold/UST Services (298%); Significant Decrease in Operating Loss (51%) AchievedInvestor Call Scheduled for Thursday, August 19, 2021 at 4:30 p.m. EDTSOUTH EASTON, MA / ACCESSWIRE / August 19, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables,...

Read more

Helix BioPharma Corp. Announces Appointment of New Director

August 19, 2021 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / August 19, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.Dr. Saczek is a Paediatric Surgeon, experienced in treating solid tumors, including...

Read more

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

August 19, 2021 8:00 AM

Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectivelyPatients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrencesNo safety issues occurred during the one-year reporting period following the study completionIRVINE, CA / ACCESSWIRE / August 19, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the...

Read more

Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.

August 19, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of pediatric cancer.Oncology Pharma is pleased to be moving forward with the development...

Read more

Phyto Extractions' Shatter Run Visits 420th Retailer on Final Leg of Cross-Country Sales Tour

August 18, 2021 4:15 PM

LANGLEY, BC / ACCESSWIRE / August 18, 2021 / Phyto Extractions Inc. (formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX)(FSE:D2EP) ("Phyto Extractions™", "Phyto" or the "Company") strives to continuously bring consumers new and innovative products to enhance their experience and overall enjoyment. Phyto Extractions™ 'is known for its iconic concentrate products and brand success, built during the legacy market era. Shatter is Phyto's...

Read more

Pressure BioSciences to Host Q2 2021 Financial Results and Business Update on Thursday, August 19, 2021

August 18, 2021 10:05 AM

Company to Discuss Strong Q2 2021 Financial Results, Give Update on Current Activities, and Take Questions on Aggressive Growth Plan Laid Out for the Company on August 5, 2021SOUTH EASTON, MA / ACCESSWIRE / August 18, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Second Quarter 2021 financial results and provide a business update. Anyone...

Read more

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering

August 17, 2021 5:45 PM

SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA, DRMAW), a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced initial public offering of 2,571,428 shares of its...

Read more